Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes pharmaceutical products. The Company develops drugs for the treatment of cystic fibrosis, cancer, inflammatory bowel, autoimmune disease, and neurological disorders. Vertex Pharmaceuticals serves the healthcare sector internationally.
Website: vrtx.com


  • Good financial results growth rate 13.3% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (4.7%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 0.0% (LTM)
  • Share price is 67.2% higher than minimum and 7.7% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (28.4x vs 26.4x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $16.2 mln (-0.014% of cap.)

Key Financials (Download financials)

Ticker: VRTX
Share price, USD:  (0.0%)476.84
year average price 446.30  


year start price 459.00 2025-02-14

max close price 513.76 2025-03-17

min close price 366.54 2025-08-08

current price 476.84 2026-02-13
Common stocks: 256 900 000

Dividend Yield:  0.0%
FCF Yield LTM: 0.0%
EV / LTM EBITDA: 28.4x
EV / EBITDA annualized: 23.7x
Last revenue growth (y/y):  +9.5%
Last growth of EBITDA (y/y):  +17.0%
Historical revenue growth:  +10.4%
Historical growth of EBITDA:  -1.0%
EV / Sales: 9.8x
Margin (EBITDA LTM / Revenue): 34.6%

Target EV / EBITDA (hist percentile): 26.4x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 122 500
Net Debt ($m): -4 762
EV (Enterprise Value): 117 738
EBITDA LTM (млн $): 4 147
EV / LTM EBITDA: 28.4x
Price to Book: 7.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-30zacks.com

Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today

2026-01-23zacks.com

Wall Street Analysts Think Vertex (VRTX) Is a Good Investment: Is It?

2026-01-22zacks.com

Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider

2026-01-12seekingalpha.com

Vertex Pharmaceuticals Incorporated (VRTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-12zacks.com

Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?

2025-12-30zacks.com

Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Momentum Stock

2025-12-08zacks.com

Why Vertex Pharmaceuticals (VRTX) is a Top Momentum Stock for the Long-Term

2025-12-03zacks.com

Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report?

2025-12-03seekingalpha.com

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

2025-11-11seekingalpha.com

Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320
fillingDate 2025-11-04 2025-08-05 2024-11-05 2024-08-02 2024-05-07 2023-11-07 2023-08-02 2023-05-02 2022-10-28
acceptedDate 2025-11-04 16:03:17 2025-08-05 16:02:33 2025-02-13 16:01:52 2024-11-05 16:11:53 2024-08-02 16:03:02 2024-05-07 16:14:28 2024-02-15 16:12:14 2023-11-07 16:16:57 2023-08-02 16:05:15 2023-05-02 16:07:33 2023-02-10 16:12:03 2022-10-28 16:07:51 2022-02-09 16:37:44 2021-02-11 16:03:06
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 3 076M 2 965M 11 020M 2 772M 2 635M 2 687M 9 869M 2 484M 2 493M 2 375M 8 931M 2 334M 7 574M 6 206M
costOfRevenue 415M 408M 1 531M 393M 372M 343M 1 262M 319M 309M 267M 1 080M 289M 904M 736M
grossProfit 2 662M 2 557M 9 490M 2 379M 2 263M 2 345M 8 607M 2 165M 2 185M 2 108M 7 850M 2 045M 6 670M 5 469M
grossProfitRatio 0.865 0.863 0.858 0.859 0.873 0.872 0.876 0.888 0.876
researchAndDevelopmentExpenses 1 032M 978M 3 630M 876M 5 416M 866M 3 163M 810M 786M 743M 2 656M 645M 3 051M 1 830M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 445M 425M 1 464M 372M 372M 343M 1 137M 264M 263M 241M 945M 247M 840M 771M
otherExpenses -2M 3M 4 628M 15M -23M -31M 476M -16M 2M 1M -58M 0 0 13M
operatingExpenses 1 475M 1 406M 9 723M 1 263M 5 788M 1 209M 4 775M 1 074M 1 048M 984M 3 543M 892M 3 891M 2 613M
costAndExpenses 1 890M 1 814M 11 253M 1 656M 6 160M 1 551M 6 037M 1 393M 1 357M 1 251M 4 623M 1 181M 4 792M 3 349M
interestIncome 126M 122M 598M 132M 157M 181M 615M 168M 145M 123M 145M 46M 5M 22M
interestExpense 3M 4M 31M 8M 10M 10M 44M 11M 11M 11M 55M 14M 62M 58M
depreciationAndAmortization 54M 52M 206M 53M 54M 54M 181M 205M 256M 469M 148M 100M 126M 110M
ebitda 1 356M 1 338M 486M 1 285M -3 327M 1 190M 4 605M 1 243M 1 283M 1 248M 4 436M 1 227M 2 918M 3 284M
ebitdaratio 0.441 0.451 0.464 -1.317 0.443 0.501 0.514 0.526 0.526
operatingIncome 1 186M 1 151M -233M 1 116M -3 525M 1 136M 3 832M 1 038M 1 026M 779M 4 307M 1 127M 2 782M 2 856M
operatingIncomeRatio 0.386 0.388 0.403 -1.338 0.423 0.418 0.412 0.328 0.483
totalOtherIncomeExpensesNet 113M 132M 481M 108M 124M 143M 548M -69M -108M 113M -75M 50M -52M 261M
incomeBeforeTax 1 299M 1 283M 249M 1 224M -3 391M 1 279M 4 380M 1 179M 1 162M 892M 4 232M 1 176M 2 730M 3 117M
incomeBeforeTaxRatio 0.422 0.433 0.442 -1.287 0.476 0.475 0.466 0.375 0.504
incomeTaxExpense 216M 250M 784M 179M 202M 180M 760M 144M 246M 192M 910M 246M 388M 405M
netIncome 1 083M 1 033M -536M 1 045M -3 594M 1 100M 3 620M 1 035M 916M 700M 3 322M 931M 2 342M 2 712M
netIncomeRatio 0.352 0.348 0.377 -1.364 0.409 0.417 0.367 0.295 0.399
eps 4.24 4.02 -2.08 4.05 -13.92 4.26 14.05 4.01 3.55 2.72 12.97 3.63 9.09 10.44
epsdiluted 4.2 3.99 4.01 -13.92 4.21 3.97 3.52 2.69 3.59
weightedAverageShsOut 256M 257M 258M 258M 258M 258M 258M 258M 258M 257M 256M 257M 258M 260M
weightedAverageShsOutDil 258M 259M 258M 261M 258M 261M 261M 261M 260M 260M 259M 260M 260M 263M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-10 2022-02-09 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 568M 571M 90M -57M -36M
ebit 279M 4 424M 4 287M 2 792M 3 175M
nonOperatingIncomeExcludingInterest -512M -592M 20M -10M -319M
netIncomeFromContinuingOperations -536M 3 620M 3 322M 2 342M 2 712M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -536M 3 620M 3 322M 2 342M 2 712M
epsDiluted -2.08 13.89 12.82 9.01 10.29

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320
fillingDate 2025-11-04 2025-08-05 2024-11-05 2024-08-02 2024-05-07 2023-11-07 2023-08-02 2023-05-02 2022-10-28
acceptedDate 2025-11-04 16:03:17 2025-08-05 16:02:33 2025-02-13 16:01:52 2024-11-05 16:11:53 2024-08-02 16:03:02 2024-05-07 16:14:28 2024-02-15 16:12:14 2023-11-07 16:16:57 2023-08-02 16:05:15 2023-05-02 16:07:33 2023-02-10 16:12:03 2022-10-28 16:07:51 2022-02-09 16:37:44 2021-02-11 16:03:06
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 4 940M 4 972M 4 570M 5 239M 4 580M 9 158M 10 369M 11 110M 10 151M 9 290M 10 504M 9 172M 6 795M 5 988M
shortTermInvestments 1 347M 1 411M 1 546M 1 285M 1 215M 1 013M 849M 11 928M 11 236M 1 124M 275M 599M 730M 671M
cashAndShortTermInvestments 6 287M 6 383M 6 116M 6 525M 5 796M 10 171M 11 218M 11 928M 11 236M 10 414M 10 779M 9 771M 7 525M 6 659M
netReceivables 1 946M 1 894M 1 609M 1 751M 1 656M 1 793M 1 563M 1 539M 1 556M 1 548M 1 442M 1 385M 1 137M 885M
inventory 1 627M 1 499M 1 205M 1 080M 915M 813M 739M 689M 604M 535M 461M 388M 353M 281M
otherCurrentAssets 709M 652M 207M 449M 575M 511M 86M 540M 477M 469M 122M 727M 104M 80M
totalCurrentAssets 10 570M 10 428M 9 596M 9 804M 8 942M 13 289M 14 144M 14 696M 13 873M 12 966M 13 235M 12 271M 9 561M 8 133M
propertyPlantEquipmentNet 3 017M 2 649M 2 585M 2 514M 1 771M 1 486M 1 453M 1 435M 1 447M 1 448M 1 456M 1 461M 1 424M 1 284M
goodwill 1 088M 1 088M 1 088M 1 088M 1 088M 1 088M 1 088M 1 088M 1 088M 1 088M 1 088M 1 075M 1 002M 1 002M
intangibleAssets 430M 436M 826M 832M 838M 835M 840M 604M 604M 604M 604M 604M 400M 400M
goodwillAndIntangibleAssets 1 518M 1 524M 1 914M 1 920M 1 926M 1 923M 1 928M 1 692M 1 692M 1 692M 1 692M 1 679M 1 402M 1 402M
longTermInvestments 5 723M 5 646M 5 108M 4 704M 4 398M 4 456M 2 498M 1 700M 1 357M 1 082M 112M 0 0 0
taxAssets 2 937M 2 712M 2 331M 2 309M 2 186M 1 963M 1 812M 1 729M 1 538M 1 360M 1 247M 1 163M 935M 883M
otherNonCurrentAssets 1 098M 1 079M 999M 990M 911M 801M 895M 475M 443M 428M 410M 133M 111M 49M
totalNonCurrentAssets 14 293M 13 609M 12 937M 12 436M 11 190M 10 629M 8 586M 7 030M 6 476M 6 009M 4 916M 4 435M 3 872M 3 618M
otherAssets 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 24 862M 24 037M 22 533M 22 240M 20 132M 23 917M 22 730M 21 726M 20 349M 18 974M 18 151M 16 706M 13 433M 11 752M
accountPayables 4 034M 442M 413M 396M 328M 351M 365M 376M 363M 323M 304M 127M 195M 155M
shortTermDebt 0 0 92M 0 0 0 0 0 0 0 0 0 0 0
taxPayables 0 0 161M 0 0 0 100M 0 0 0 123M 0 211M 104M
deferredRevenue 0 0 207M 0 128M 276M 170M 0 0 0 160M 0 172M 192M
otherCurrentLiabilities 442M 3 696M 225M 3 577M 3 219M 3 169M 51M 3 224M 2 989M 2 703M 63M 2 482M 17M 84M
totalCurrentLiabilities 4 475M 4 138M 3 565M 3 973M 3 547M 3 796M 3 547M 3 599M 3 352M 3 026M 2 742M 2 609M 2 142M 1 878M
longTermDebt 1 835M 1 527M 0 1 703M 1 867M 721M 0 745M 768M 789M 0 825M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 1 233M 1 196M 902M 933M -57M 854M 878M 869M 759M 727M 686M 941M 303M 298M
totalNonCurrentLiabilities 3 068M 2 723M 2 559M 2 636M 1 810M 1 575M 1 602M 1 614M 1 527M 1 516M 1 496M 1 068M 1 191M 1 188M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 1 835M 1 527M 1 657M 1 703M 933M 721M 808M 745M 768M 789M 900M 825M 967M 932M
totalLiabilities 7 544M 6 861M 6 124M 6 609M 5 357M 5 371M 5 150M 5 213M 4 879M 4 542M 4 238M 3 677M 3 333M 3 065M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 3M 3M 3M 3M 3M 3M 3M 258M 258M 3M 3M 3M 3M 3M
retainedEarnings 12 369M 11 286M 9 607M 8 694M 7 648M 11 242M 10 142M 9 174M 8 138M 7 223M 6 523M 5 704M 3 201M 859M
accumulatedOtherComprehensiveIncomeLoss -65M -101M 128M 29M 23M 17M -14M -3M -40M -13M 800 000 98M 16M -68M
othertotalStockholdersEquity 5 012M 5 988M 6 906M 7 101M 7 285M 7 084M 7 114M 7 220M 7 226M
totalStockholdersEquity 17 319M 17 175M 16 410M 15 631M 14 775M 18 547M 17 580M 16 513M 15 470M 14 432M 13 913M 13 030M 10 100M 8 687M
totalEquity 17 319M 17 175M 16 410M 15 631M 14 775M 18 547M 17 580M 16 513M 15 470M 14 432M 13 913M 13 030M 10 100M 8 687M
totalLiabilitiesAndStockholdersEquity 24 862M 24 037M 22 240M 20 132M 23 917M 21 726M 20 349M 18 974M 16 706M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 24 862M 24 037M 22 533M 22 240M 20 132M 23 917M 22 730M 21 726M 20 349M 18 974M 18 151M 16 706M 13 433M 11 752M
totalInvestments 7 070M 7 057M 6 654M 5 989M 5 613M 5 469M 3 347M 13 628M 12 594M 2 206M 387M 599M 730M 671M
totalDebt 1 835M 1 527M 1 750M 1 703M 933M 721M 808M 745M 768M 789M 900M 825M 967M 932M
netDebt -3 105M -3 445M -2 820M -3 536M -3 647M -8 437M -9 561M -10 366M -9 384M -8 501M -9 604M -8 347M -5 828M -5 056M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-10 2022-02-09 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 1 609M 1 563M 1 442M 1 137M 885M
otherReceivables 0 0 0 0 0
prepaids 459M 538M 432M 442M 229M
totalPayables 413M 925M 642M 607M 425M
otherPayables 0 560M 338M 412M 270M
accruedExpenses 2 628M 2 318M 1 788M 1 267M 1 135M
capitalLeaseObligationsCurrent 0 84M 89M 80M 42M
capitalLeaseObligationsNonCurrent 1 657M 725M 810M 887M 890M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 6 672M 7 450M 7 387M 6 881M 7 894M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX VRTX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320 875 320
fillingDate 2025-11-04 2025-08-05 2024-11-05 2024-08-02 2024-05-07 2023-11-07 2023-08-02 2023-05-02 2022-10-28
acceptedDate 2025-11-04 16:03:17 2025-08-05 16:02:33 2025-02-13 16:01:52 2024-11-05 16:11:53 2024-08-02 16:03:02 2024-05-07 16:14:28 2024-02-15 16:12:14 2023-11-07 16:16:57 2023-08-02 16:05:15 2023-05-02 16:07:33 2023-02-10 16:12:03 2022-10-28 16:07:51 2022-02-09 16:37:44 2021-02-11 16:03:06
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 1 083M 1 033M -536M 1 045M -3 594M 1 100M 3 620M 1 035M 916M 700M 3 322M 931M 2 342M 2 712M
depreciationAndAmortization 54M 52M 207M 53M 54M 54M 181M 42M 41M 39M 148M 37M 126M 110M
deferredIncomeTax -236M -114M -349M -123M -119M -158M -537M -116M -177M -113M -276M -182M -155M 277M
stockBasedCompensation 195M 167M 699M 185M 154M 192M 581M 131M 119M 122M 491M 136M 441M 430M
changeInWorkingCapital 401M -132M -515M 112M -241M 129M -266M 189M 245M 139M 341M 81M -105M -54M
accountsReceivables -60M -18M -99M -52M 135M -252M -84M -6M -3M -91M -359M -120M -275M -223M
inventory -131M -149M -517M -183M -107M -80M -323M -98M -73M -83M -136M -27M -93M -132M
accountsPayables -35M 8M 50M 66M -25M 100 000 49M 9M 36M 36M 121M -70M 32M 51M
otherWorkingCapital 627M 27M 52M 280M -244M 461M 93M 283M 286M 137M 715M 297M 230M 250M
otherNonCashItems -255M 67M 900 000 98M 251M 621M -43M -13M -11M 13M 103M -46M -6M -220M
netCashProvidedByOperatingActivities 1 241M 1 073M -493M 1 370M -3 754M 1 307M 3 537M 1 268M 1 134M 900M 4 130M 956M 2 644M 3 254M
investmentsInPropertyPlantAndEquipment -102M -146M -298M -68M -77M -248M -200M -41M -60M -42M -205M -54M -235M -260M
acquisitionsNet 0 0 0 0 0 0 0 1M 0 25M -296M 0 77M -418M
purchasesOfInvestments -1 345M -2 173M -7 696M -1 127M -1 555M -2 599M -3 787M -408M -579M -1 842M -693M -228M -605M -451M
salesMaturitiesOfInvestments 1 329M 1 839M 4 466M 1 112M 1 183M 711M 934M 331M 335M 50M 920M 194M 499M 810M
otherInvestingActivites 800 000 -4M -266M -15M -180M -1M 0 -25M -296M
netCashUsedForInvestingActivites -117M -485M -348M -464M -2 136M -118M -304M -1 834M -384M
debtRepayment -1M -1M -5M -14M -13M -11M -11M -11M -50M
commonStockIssued 0 0 8M 0 17M 15M 0 14M 0
commonStockRepurchased 1 094M -398M -1 582M -391M -401M -131M -654M -170M -31M -299M -172M -48M -1 561M -539M
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -2 249M 50M -83M 56M -230M 17M 60M 1M 37M
netCashUsedProvidedByFinancingActivities -1 155M -349M -388M -359M -358M -165M 17M -295M -60M
effectOfForexChangesOnCash -4M 57M -43M 23M -3M -16M 27M -23M 10M 12M -29M -38M -13M 21M
netChangeInCash -34M 297M -5 800M 668M -4 578M -1 214M -140M 963M 858M -1 216M 3 712M 473M 811M 2 868M
cashAtEndOfPeriod 4 948M 4 982M 4 572M 5 248M 4 580M 9 158M 10 372M 11 117M 10 153M 9 296M 10 512M 9 177M 6 800M 5 989M
cashAtBeginningOfPeriod 4 982M 4 685M 10 372M 4 580M 9 158M 10 372M 10 512M 10 153M 9 296M 10 512M 6 800M 8 704M 5 989M 3 121M
operatingCashFlow 1 241M 1 073M -493M 1 370M -3 754M 1 307M 3 537M 1 268M 1 134M 900M 4 130M 956M 2 644M 3 254M
capitalExpenditure -102M -146M -298M 120M -77M -248M -258M -41M -60M -42M -205M -54M -235M -260M
freeCashFlow 1 140M 927M -790M 1 490M -3 830M 1 058M 3 279M 1 228M 1 075M 858M 3 925M 901M 2 409M 2 994M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-10 2022-02-09 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -242M -89M -48M -77M 418M
netCashProvidedByInvestingActivities -3 770M -3 142M -321M -341M 99M
netDebtIssuance -34M -45M -82M -19M -29M
longTermNetDebtIssuance -34M -45M -82M -19M -29M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -1 582M -654M -172M -1 561M -274M
netCommonStockIssuance -1 582M -654M -172M -1 561M -274M
commonStockIssuance 0 0 0 0 265M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 121M 136M 186M 102M -202M
netCashProvidedByFinancingActivities -1 495M -562M -68M -1 478M -505M
incomeTaxesPaid 1 082M 1 677M 1 058M 476M 192M
interestPaid 31M 43M 52M 56M 55M

Earning call transcript

2025 q3
2025-11-03 ET (fiscal 2025 q3)
2025 q2
2025-08-04 ET (fiscal 2025 q2)
2025 q1
2025-05-05 ET (fiscal 2025 q1)
2024 q4
2025-02-10 ET (fiscal 2024 q4)
2024 q3
2024-11-04 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-06 ET (fiscal 2024 q1)
2023 q4
2024-02-05 ET (fiscal 2023 q4)
2023 q3
2023-11-06 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-05-01 ET (fiscal 2023 q1)
2022 q4
2023-02-07 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-02-12 21:04 ET
Vertex Pharmaceuticals published news for 2025 q4
SEC form 8
2026-02-12 21:04 ET
Vertex Pharmaceuticals reported for 2025 q4
SEC form 8
2025-11-03 16:06 ET
Vertex Pharmaceuticals published news for 2025 q3
SEC form 8
2025-11-03 16:06 ET
Vertex Pharmaceuticals reported for 2025 q3
SEC form 8
2025-08-04 20:06 ET
Vertex Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-04 20:06 ET
Vertex Pharmaceuticals reported for 2025 q2
SEC form 10
2025-05-06 00:00 ET
Vertex Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-05 00:00 ET
Vertex Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-05 00:00 ET
Vertex Pharmaceuticals reported for 2025 q1
SEC form 10
2025-02-13 00:00 ET
Vertex Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-10 16:08 ET
Vertex Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-10 16:08 ET
Vertex Pharmaceuticals reported for 2024 q4
SEC form 10
2024-11-05 16:11 ET
Vertex Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-04 16:02 ET
Vertex Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-04 16:02 ET
Vertex Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-02 16:03 ET
Vertex Pharmaceuticals published news for 2024 q2
SEC form 10
2024-08-02 00:00 ET
Vertex Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-01 16:05 ET
Vertex Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-01 16:05 ET
Vertex Pharmaceuticals reported for 2024 q2
SEC form 10
2024-05-07 16:14 ET
Vertex Pharmaceuticals published news for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Vertex Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-06 16:03 ET
Vertex Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-06 16:03 ET
Vertex Pharmaceuticals reported for 2024 q1
SEC form 10
2024-02-15 00:00 ET
Vertex Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-05 00:00 ET
Vertex Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-05 00:00 ET
Vertex Pharmaceuticals reported for 2023 q4
SEC form 10
2023-11-07 16:16 ET
Vertex Pharmaceuticals published news for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Vertex Pharmaceuticals published news for 2023 q3
SEC form 8
2023-11-06 16:05 ET
Vertex Pharmaceuticals reported for 2023 q3
SEC form 10
2023-08-02 16:05 ET
Vertex Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Vertex Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-01 16:03 ET
Vertex Pharmaceuticals reported for 2023 q2
SEC form 8
2023-08-01 00:00 ET
Vertex Pharmaceuticals published news for 2023 q2
SEC form 10
2023-05-02 00:00 ET
Vertex Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-01 00:00 ET
Vertex Pharmaceuticals reported for 2023 q1
SEC form 10
2023-02-10 16:12 ET
Vertex Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-10 00:00 ET
Vertex Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-07 16:07 ET
Vertex Pharmaceuticals published news for 2022 q4
SEC form 8
2023-02-07 00:00 ET
Vertex Pharmaceuticals reported for 2022 q4
SEC form 10
2022-10-28 16:07 ET
Vertex Pharmaceuticals reported for 2022 q3
SEC form 10
2022-10-28 00:00 ET
Vertex Pharmaceuticals reported for 2022 q3
SEC form 6
2022-10-27 16:06 ET
Vertex Pharmaceuticals published news for 2022 q3
SEC form 8
2022-10-27 00:00 ET
Vertex Pharmaceuticals reported for 2022 q3
SEC form 6
2022-09-21 16:05 ET
Vertex Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-05 16:06 ET
Vertex Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-05 00:00 ET
Vertex Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-04 16:08 ET
Vertex Pharmaceuticals published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Vertex Pharmaceuticals reported for 2022 q2
SEC form 6
2022-07-11 08:14 ET
Vertex Pharmaceuticals published news for 2022 q2
SEC form 6
2022-07-05 16:08 ET
Vertex Pharmaceuticals published news for 2022 q2
SEC form 6
2022-05-23 08:41 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-18 16:09 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-18 16:01 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-06 16:03 ET
Vertex Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-06 00:00 ET
Vertex Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-05 16:04 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Vertex Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-03 17:41 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-03 16:44 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-03 16:42 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-12 16:05 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-07 16:05 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-06 16:59 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 10
2022-02-09 16:37 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-09 00:00 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:29 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:27 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:26 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:24 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:21 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:19 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:17 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:14 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:12 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:09 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:06 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-01 16:09 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-26 16:05 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-26 00:00 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-19 16:24 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-19 16:21 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-03 16:18 ET
Vertex Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
Vertex Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-02 16:05 ET
Vertex Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Vertex Pharmaceuticals published news for 2021 q3
SEC form 10
2021-07-30 16:10 ET
Vertex Pharmaceuticals published news for 2021 q2
SEC form 10
2021-07-30 00:00 ET
Vertex Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-29 16:05 ET
Vertex Pharmaceuticals published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Vertex Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-24 07:41 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-19 16:02 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-03 17:05 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 10
2021-04-30 16:19 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 10
2021-04-30 00:00 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-29 16:09 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-20 08:03 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-08 16:03 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 6
2021-03-08 16:05 ET
Vertex Pharmaceuticals published news for 2020 q4
SEC form 10
2021-02-11 16:03 ET
Vertex Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-05 16:38 ET
Vertex Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-01 16:05 ET
Vertex Pharmaceuticals published news for 2020 q4
SEC form 6
2020-11-20 08:48 ET
Vertex Pharmaceuticals published news for 2020 q3
SEC form 10
2020-10-30 16:13 ET
Vertex Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-29 16:04 ET
Vertex Pharmaceuticals published news for 2020 q3